Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nonhormonal Management of VMS

NAMS issues updated position statement

The North American Menopause Society’s (NAMS) updated position statement on nonhormonal management of menopause-associated vasomotor symptoms (VMS) offers recommendations and cautions to clinicians on the array of nonhormonal management options currently available to midlife women to help prevent underuse of effective therapies or use of inappropriate or ineffective therapies.

Among the recommendations are:

• Cognitive-behavioral therapy, and to a lesser degree, clinical hypnosis.

• Paroxetine salt is the only FDA-approval nonhormonal medication for the management of VMS.

Recommend with caution:

• Weight loss

• Mindfulness-based stress reduction

• S-equol derivative of soy isoflavones

• Stellate ganglion block

Do not recommend at this time:

• Cooling techniques

• Avoidance of triggers

• Exercise, yoga, paced respiration

• Relaxation

• Over-the-counter supplements and herbal therapies

• Acupuncture, calibration of neural oscillations, chiropractic interventions

Citation: Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. [Published online ahead of print September 21, 2015]. doi: 10.1097/GME.0000000000000546.